Lumenis and Trimedyne Settle Litigation

Lumenis and Trimedyne Settle Litigation 


YOKNEAM, Israel, Dec. 16   /PRNewswire-FirstCall/ -- Lumenis Ltd.  and
Trimedyne, Inc.  (BULLETIN BOARD: TMED)  today announced they have agreed to a
settlement of the litigation between them.

Under the terms of the settlement, Lumenis and Trimedyne have agreed to enter
into a long term commercial arrangement covering the manufacture by Trimedyne
and sale by Lumenis of certain side fire and angle fire fibers, used with
Lumenis' lasers particularly in orthopedics, urology and spinal surgery. The
settlement includes certain other confidential terms.

The arrangement will give Lumenis immediate entry into the market for
side-firing laser devices for use in spinal treatments, one of the fastest
growing segments of the healthcare field.  Trimedyne's side-firing Laser
Needles, which are only one-twelfth of an inch in diameter, are the leading
laser devices used in the outpatient treatment of herniated or ruptured lumbar
discs in the spine.  The laser procedure is usually performed with local
anesthetic in about 20-30 minutes.  Patients typically leave the hospital or
surgery center within an hour after the procedure, with only a Band-Aid on the
puncture.  Most can return to light daily activities within a few days.

About Lumenis

Lumenis develops, manufactures, and markets state-of-the-art proprietary laser
and intense pulsed light devices. Its systems are used in a variety of
aesthetic, ophthalmic, surgical and dental applications, including skin
treatments, hair removal, non-invasive treatment of vascular lesions and
pigmented lesions, acne, psoriasis, ENT, gynecology, urinary lithotripsy, benign
prostatic hyperplasia, open angle glaucoma, diabetic retinopathy, secondary
cataracts, age-related macular degeneration, vision correction, neurosurgery,
dentistry and veterinary. For more information about Lumenis and its products
log on to http://www.lumenis.com/

About Trimedyne

Trimedyne is a leading manufacturer of surgical lasers and proprietary
disposable and reusable fiber optic devices for applications in a variety of
minimally invasive surgical procedures in orthopedics (discectomy and
arthroscopy), lithotripsy (fragmentation of stones), ENT surgery, gynecology,
gastrointestinal surgery and general surgery.  For product, financial or other
information, visit Trimedyne's website at http://www.trimedyne.com/.

The statements in this press release that are not historical facts are
forward-looking statements which are subject to risks and uncertainties.
Lumenis' actual results could differ materially from those anticipated in the
forward looking statements based on a variety of factors, including, among
others: uncertainties with respect to market acceptance of Lumenis' products,
obtaining regulatory approvals for new products or for the sale of existing
products in new markets and enforcement of intellectual property rights; risks
associated with competition and competitive pricing pressures, economic
conditions generally, Lumenis' international operations and Lumenis' ability to
integrate its operations with those of acquired businesses; the outcome of the
Securities and Exchange Commission investigation and several securities class
action lawsuits to which Lumenis is subject; uncertainties relating to Lumenis'
continuing liquidity; and other risks detailed from time to time in the reports
filed by Lumenis with the SEC, including its annual report on Form 10-K and
quarterly reports on Form 10-Q.

   Contacts:  Kevin Morano
              CFO
              212-515-4187


DATASOURCE: Lumenis Ltd.



CONTACT:  Kevin Morano, CFO of Lumenis Ltd., [phone]



Web site:  http://www.lumenis.com/

http://www.trimedyne.com/ 

Copyright